Most Viewed Articles - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Most Viewed Articles

US Pharmacopeial Convention Announces Revised Official Dates for Elemental Impurities Chapters

January 31, 2013

ePT--the Electronic Newsletter of Pharmaceutical Technology

Two general chapters on elemental impurities? limits and procedures are to become official Feb. 1, 2013, with implementation proposed for May 1, 2014.

Endo Pharmaceuticals and GVK Biosciences Form Research Collaboration

January 30, 2013

ePT--the Electronic Newsletter of Pharmaceutical Technology

Endo Pharmaceuticals and GVK Biosciences (GVK BIO), a contract research organisation (CRO) based in India, have entered into an agreement to collaborate on the development of small molecules targeting an undisclosed protein. Using its discovery expertise, GVK BIO will deliver a clinical candidate and Endo will be responsible for the development and commercialisation of the product.

Ben Venue Laboratories Enters Consent Decree

January 29, 2013

ePT--the Electronic Newsletter of Pharmaceutical Technology

Ben Venue Laboratories announced that it has voluntarily entered into a consent decree with FDA over violations of cGMP.

GSK in Joint Venture for Pediatric Vaccine

January 28, 2013

ePT--the Electronic Newsletter of Pharmaceutical Technology

GlaxoSmithKline has formed a joint venture with Indian vaccines company Biological E to research and develop a six-in-one combination pediatric vaccine to help protect children in India and other developing countries from certain infectious diseases.

Actavis Unveils Long-Term Growth Strategy

January 25, 2013

ePT--the Electronic Newsletter of Pharmaceutical Technology

Following its recent acquisition, Actavis (formerly Watson Pharmaceuticals) unveiled its long-term growth strategy during its investor meeting in New York.

FDA Approves New Influenza Vaccine Manufactured with Novel Technology

January 18, 2013

ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA has approved Protein Sciences's FluBlok, a seasonal influenza vaccine made with novel technology. FluBlok uses recombinant DNA and a modified baculovirus (a virus that infects insects) to produce a safe and effective human flu vaccine. FDA approved Flublok for people 18–49 years old.

Hameln Pharmaceuticals Receives FDA Warning Letter

January 16, 2013

ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA has issued a Warning Letter to Hameln Pharmaceuticals GmbH after observing "significant" cGMP violations for finished pharmaceuticals at the company?s facility in Hameln, Germany.

EMA Updates Guideline for Anticancer Medicines

January 14, 2013

ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Medicines Agency has revised its guideline for the evaluation of anticancer medicinal products.

AbbVie Celebrates Official Launch

January 7, 2013

ePT--the Electronic Newsletter of Pharmaceutical Technology

AbbVie, a research-focused, specialty biopharmaceutical company that was spun off from Abbott Pharmaceuticals, was officially launched on Jan. 2, 2013

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Click here